| abstract |
The present invention relates to a chemotherapeutic cancer treatment in which compounds of Formula la', lb', Ic', or II' (referred to as a group as BH3ls) are administered to a mammal for the treatment of B-cell Lymphoma or other hematopoietic cancers, including diseases associated with MeL-l. In another aspect, the invention provides a method for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more compounds selected from the group consisting of compounds of la', lb', Ic', or II' in combination with other therapies, for example, a class of therapeutics known as 26S proteosome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with pharmaceutical compositions comprising one or more compounds of Formula la', lb', Ic', or II'. |